tumors of the genitourinary system
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for the Dermatitis Group (D Group): (1) A confirmed diagnosis of advanced RCC or UC and having received at least one cycle of ICI treatment during the study; (2) A clear diagnosis of immune-related skin adverse events confirmed jointly by dermatologists and urologists; (3) Adults aged 18-75 years. 2. Inclusion criteria for the Control Group (N Group): (1) A confirmed diagnosis of advanced RCC or UC and having received at least one cycle of ICI treatment during the study;(2) Clinically confirmed by physicians during follow-up that no immune-related skin adverse events occurred; (3) Adults aged 18-75 years.
Exclusion criteria
Exclusion criteria: 1. Patients with active, uncontrolled skin diseases (such as psoriasis or acute eczema) at the start of ICI therapy; 2. Pregnant patients; 3. Patients under 18 years old and over 75 years old; 4. Patients who are hemodynamically unstable; 5. Patients who have used systemic immunosuppressants (such as glucocorticoids, except for prophylactic use or for non-autoimmune conditions) within 4 weeks before ICI therapy; 6. Other situations that may confound the assessment of dermatitis, such as a clear history of other drug allergies, rashes caused by active infections, and dermatitis caused by other medications; 7. Patients unwilling to participate in the study; 8. Patients with incomplete clinical data (medical records and test results, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| General information of the patient (including age, gender, height, weight, BMI);Blood biochemical indicators;Complete blood count indicators; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinalysis indicators; | — |
Countries
China
Contacts
Beijing Friendship Hospital ,Capital Medical University